Regulatory News: Sensorion (FR0012596468 ? ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss ...

Gilead Sciences, Inc. today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis (PBC) in ...

Raichur: Shilpa Medicare Limited, recently announced that its Investigational New Drug (IND), Nor-Ursodeoxycholic Acid ...

Primary Biliary Cholangitis Clinical Trial Pipeline Pharmaceutical companies are advancing the Primary Biliary Cholangitis treatment pipeli ...

The trials identified no serious adverse effects, and patients tolerated a daily dosage of 1500 mg for 24 weeks.

Shilpa Medicare announces the approval of its IND - Nor Ursodeoxycholic Acid Tablets 500 mg, by the Subject Expert Committee of CDSCO. The Committee has further recommended grant of marketing ...

Non-alcoholic fatty liver disease (NAFLD) affects nearly 19 crore people in India and about a quarter of the world’s ...

The spike in Shilpa Medicare's stock price came after the company announced the approval of its Investigational New Drug (IND ...

Biotech giant Gilead Sciences, Inc. GILD is scheduled to report fourth-quarter and full-year 2024 results on Feb. 11, after market close. The Zacks Consensus Estimate for sales and earnings is ...

These 12 studies could also be categorized into groups by UDCA dosage, or by UDCA Monotherapy or UDCA combined with other drugs. All 12 studies included end-point results presented as concrete ...

The prescribed dosage for fluoxetine may depend on a person’s individual treatment plan. Other factors, including your specific diagnosis, body weight, and medical history, may affect your ...

or intolerant of UDCA, is considered. We recommend dose adjustment in patients with advanced liver disease as per the drug label (Strong; Low). We recommend all patients should be evaluated for the ...